Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SLS
HoldHot AirSELLAS Life Sciences Group, Inc. · Healthcare · United States · $2.7B · Avg Vol: $89M/d
COMPANY DESCRIPTION
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapies. The company's competitive moat is its lead product candidate, galinpepimut-S (GPS), a WT1-targeting immunotherapy designed to address a wide range of hematologic malignancies and solid tumors. It operates as a niche biotechnology developer targeting unmet needs in oncology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.0M | 0 | 0 | 0 | — | — | — | 53.1M | 121.3% |
| EPS | — | -0.23 | -0.22 | -0.19 | -0.25 | — | -0.22 | -0.20 | -0.10 | — |
| Shares | — | 196.6M | 196.6M | 196.6M | 153.1M | -22.1% | 201.9M | — | — | — |
| Debt | — | 0.9M | 0.9M | 1.0M | 1.0M | 1.9% | 0.7M | — | — | — |
| Equity | — | 4.9M | -8.0M | 9.5M | 70.9M | 144.5% | — | — | — | — |
| Op CF | — | -23.8M | -31.4M | -35.4M | -28.4M | — | -28.4M | — | — | — |
| Inv CF | 0 | -4.5M | -5.5M | 0 | — | — | — | — | — | — |
| Fin CF | — | 24.1M | 22.3M | 46.8M | 86.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SLS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SLS | SELLAS Life Sciences Group, Inc.(you) | $2.7B | 44 | Hold |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.1B | 44 | Hold |
| SRPT | Sarepta Therapeutics, Inc. | $2.2B | 46 | Hold |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.0B | 50 | Hold |
| IOVA | Iovance Biotherapeutics, Inc. | $3.6B | 39 | Hold |
| URGN | UroGen Pharma Ltd. | $2.1B | 51 | Hold |
| ADMA | ADMA Biologics, Inc. | $2.1B | 53 | Hold |
| SEPN | Septerna, Inc. | $1.8B | 52 | Hold |
| NUVB | Nuvation Bio Inc. | $2.3B | 31 | Sell |
| NRIX | Nurix Therapeutics, Inc. | $2.7B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%